Palisade Bio, Inc. (PALI) — 8-K Filings

8-K Filings (24)

• Palisade Bio Files 8-K: Other Events — Apr 2, 2026 Risk: low
  Palisade Bio, Inc. filed an 8-K on April 2, 2026, reporting other events as of March 27, 2026. The filing does not contain specific financial details or signifi
• Palisade Bio Files 8-K with Corporate Updates — Dec 4, 2025 Risk: low
  Palisade Bio, Inc. filed an 8-K on December 4, 2025, reporting events that occurred on December 3, 2025. The filing indicates changes to its Articles of Incorpo
• Palisade Bio Announces Director and Officer Changes — Oct 22, 2025 Risk: medium
  On October 21, 2025, Palisade Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indi
• Palisade Bio Files 8-K on Security Holder Votes — Oct 20, 2025 Risk: low
  Palisade Bio, Inc. filed an 8-K on October 20, 2025, reporting on matters submitted to a vote of its security holders as of October 17, 2025. The filing details
• Palisade Bio Relocates Principal Executive Offices — Oct 16, 2025 Risk: low
  On October 15, 2025, Palisade Bio, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1902 Wright Place, Su
• Palisade Bio Files 8-K: Financial Statements and Exhibits — Oct 9, 2025 Risk: low
  On October 9, 2025, Palisade Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or
• Palisade Bio Relocates Headquarters — Sep 26, 2025 Risk: low
  On September 26, 2025, PALISADE BIO, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1902 Wright Place,
• Palisade Bio Relocates Principal Executive Offices — Sep 18, 2025 Risk: low
  On September 18, 2025, Palisade Bio, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1902 Wright Place,
• Palisade Bio, Inc. Reports Board Changes — Sep 5, 2025 Risk: low
  Palisade Bio, Inc. announced on September 4, 2025, a change in its board of directors. Specifically, the company reported the departure of a director and the el
• Palisade Bio, Inc. Files 8-K: Material Agreement & Equity Sales — Jul 25, 2025 Risk: medium
  On July 23, 2025, Palisade Bio, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also
• Palisade Bio Appoints New CEO, Board Changes — Jul 9, 2025 Risk: medium
  Palisade Bio, Inc. announced on July 2, 2025, a change in its board of directors. Specifically, Dr. David J. Mazzo has been appointed as the new Chief Executive
• Palisade Bio Faces Delisting Concerns — May 2, 2025 Risk: high
  Palisade Bio, Inc. filed an 8-K on May 2, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April 29, 2025.
• Palisade Bio Announces Material Agreement and Equity Sales — Dec 16, 2024 Risk: medium
  On December 16, 2024, Palisade Bio, Inc. announced a material definitive agreement with an unnamed party. The company also disclosed unregistered sales of equit
• Palisade Bio Appoints New CEO — Sep 27, 2024 Risk: medium
  Palisade Bio, Inc. announced on September 27, 2024, that its Board of Directors appointed Dr. Jonathan M. Frampton as Chief Executive Officer, effective Septemb
• Palisade Bio Files 8-K on Security Holder Vote — Jul 8, 2024 Risk: low
  On July 8, 2024, Palisade Bio, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not contain det
• Palisade Bio Appoints New CMO and CSO — May 10, 2024 Risk: medium
  Palisade Bio, Inc. announced on May 7, 2024, the appointment of Dr. Robert E. Smith as Chief Medical Officer and Dr. Jonathan M. Roth as Chief Scientific Office
• Palisade Bio Secures $1.5M Convertible Note Financing — May 3, 2024 Risk: medium
  On May 1, 2024, Palisade Bio, Inc. entered into a Material Definitive Agreement, specifically a Convertible Promissory Note Purchase Agreement with an investor.
• Palisade Bio Files 8-K Report — Apr 10, 2024 Risk: low
  On April 10, 2024, Palisade Bio, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Seneca Biopharma, Inc.
• Palisade Bio Relocates Principal Offices — Apr 5, 2024 Risk: low
  Palisade Bio, Inc. filed an 8-K on April 5, 2024, reporting a change in its principal executive offices to 7750 El Camino Real, Suite 2A, Carlsbad, California,
• Palisade Bio Faces Nasdaq Delisting Warning — Mar 27, 2024 Risk: medium
  Palisade Bio, Inc. announced on March 27, 2024, that it received a determination letter from The Nasdaq Stock Market LLC on March 22, 2024, indicating non-compl
• Palisade Bio Appoints Dr. Jonathan T. Hunt as CEO — Mar 6, 2024 Risk: medium
  Palisade Bio, Inc. announced on March 6, 2024, that its Board of Directors appointed Dr. Jonathan T. Hunt as Chief Executive Officer, effective February 29, 202
• Palisade Bio Reports Officer/Director Changes in 8-K — Feb 13, 2024 Risk: medium
  PALISADE BIO, INC. filed an 8-K on February 13, 2024, reporting events related to the "Departure of Directors or Certain Officers; Election of Directors; Appoin
• PALISADE BIO Sells Equity in Unregistered Offering — Feb 1, 2024
  PALISADE BIO, INC. (PALI) entered into a material definitive agreement on January 30, 2024, involving the unregistered sale of equity securities. This 8-K filin
• PALISADE BIO Files 8-K for Regulation FD Disclosure — Jan 29, 2024
  PALISADE BIO, INC. filed an 8-K on January 29, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibits. This f

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX